Cargando…
Complement Activation Products in Patients with Chronic Schizophrenia
Evidence suggests a role of the immune system in the pathogenesis of a number of mental conditions, including schizophrenia (SCH). In terms of physiology, aside from its crucial protective function, the complement cascade (CC) is a critical element of the regeneration processes, including neurogenes...
Autores principales: | , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9967657/ https://www.ncbi.nlm.nih.gov/pubmed/36836111 http://dx.doi.org/10.3390/jcm12041577 |
_version_ | 1784897319519387648 |
---|---|
author | Rudkowski, Krzysztof Waszczuk, Katarzyna Tyburski, Ernest Rek-Owodziń, Katarzyna Plichta, Piotr Podwalski, Piotr Bielecki, Maksymilian Mak, Monika Michalczyk, Anna Tarnowski, Maciej Sielatycka, Katarzyna Budkowska, Marta Łuczkowska, Karolina Dołęgowska, Barbara Ratajczak, Mariusz Z. Samochowiec, Jerzy Kucharska-Mazur, Jolanta Sagan, Leszek |
author_facet | Rudkowski, Krzysztof Waszczuk, Katarzyna Tyburski, Ernest Rek-Owodziń, Katarzyna Plichta, Piotr Podwalski, Piotr Bielecki, Maksymilian Mak, Monika Michalczyk, Anna Tarnowski, Maciej Sielatycka, Katarzyna Budkowska, Marta Łuczkowska, Karolina Dołęgowska, Barbara Ratajczak, Mariusz Z. Samochowiec, Jerzy Kucharska-Mazur, Jolanta Sagan, Leszek |
author_sort | Rudkowski, Krzysztof |
collection | PubMed |
description | Evidence suggests a role of the immune system in the pathogenesis of a number of mental conditions, including schizophrenia (SCH). In terms of physiology, aside from its crucial protective function, the complement cascade (CC) is a critical element of the regeneration processes, including neurogenesis. Few studies have attempted to define the function of the CC components in SCH. To shed more light on this topic, we compared the levels of complement activation products (CAP) (C3a, C5a and C5b-9) in the peripheral blood of 62 patients with chronic SCH and disease duration of ≥ 10 years with 25 healthy controls matched for age, sex, BMI and smoking status. Concentrations of all the investigated CAP were elevated in SCH patients. However, after controlling for potential confounding factors, significant correlations were observed between SCH and C3a (M = 724.98 ng/mL) and C5a (M = 6.06 ng/mL) levels. In addition, multivariate logistic regression showed that C3a and C5b-9 were significant predictors of SCH. There were no significant correlations between any CAP and SCH symptom severity or general psychopathology in SCH patients. However, two significant links emerged between C3a and C5b-9 and global functioning. Increased levels of both complement activation products in the patient group as compared to healthy controls raise questions concerning the role of the CC in the etiology of SCH and further demonstrate dysregulation of the immune system in SCH patients. |
format | Online Article Text |
id | pubmed-9967657 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-99676572023-02-27 Complement Activation Products in Patients with Chronic Schizophrenia Rudkowski, Krzysztof Waszczuk, Katarzyna Tyburski, Ernest Rek-Owodziń, Katarzyna Plichta, Piotr Podwalski, Piotr Bielecki, Maksymilian Mak, Monika Michalczyk, Anna Tarnowski, Maciej Sielatycka, Katarzyna Budkowska, Marta Łuczkowska, Karolina Dołęgowska, Barbara Ratajczak, Mariusz Z. Samochowiec, Jerzy Kucharska-Mazur, Jolanta Sagan, Leszek J Clin Med Article Evidence suggests a role of the immune system in the pathogenesis of a number of mental conditions, including schizophrenia (SCH). In terms of physiology, aside from its crucial protective function, the complement cascade (CC) is a critical element of the regeneration processes, including neurogenesis. Few studies have attempted to define the function of the CC components in SCH. To shed more light on this topic, we compared the levels of complement activation products (CAP) (C3a, C5a and C5b-9) in the peripheral blood of 62 patients with chronic SCH and disease duration of ≥ 10 years with 25 healthy controls matched for age, sex, BMI and smoking status. Concentrations of all the investigated CAP were elevated in SCH patients. However, after controlling for potential confounding factors, significant correlations were observed between SCH and C3a (M = 724.98 ng/mL) and C5a (M = 6.06 ng/mL) levels. In addition, multivariate logistic regression showed that C3a and C5b-9 were significant predictors of SCH. There were no significant correlations between any CAP and SCH symptom severity or general psychopathology in SCH patients. However, two significant links emerged between C3a and C5b-9 and global functioning. Increased levels of both complement activation products in the patient group as compared to healthy controls raise questions concerning the role of the CC in the etiology of SCH and further demonstrate dysregulation of the immune system in SCH patients. MDPI 2023-02-16 /pmc/articles/PMC9967657/ /pubmed/36836111 http://dx.doi.org/10.3390/jcm12041577 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Rudkowski, Krzysztof Waszczuk, Katarzyna Tyburski, Ernest Rek-Owodziń, Katarzyna Plichta, Piotr Podwalski, Piotr Bielecki, Maksymilian Mak, Monika Michalczyk, Anna Tarnowski, Maciej Sielatycka, Katarzyna Budkowska, Marta Łuczkowska, Karolina Dołęgowska, Barbara Ratajczak, Mariusz Z. Samochowiec, Jerzy Kucharska-Mazur, Jolanta Sagan, Leszek Complement Activation Products in Patients with Chronic Schizophrenia |
title | Complement Activation Products in Patients with Chronic Schizophrenia |
title_full | Complement Activation Products in Patients with Chronic Schizophrenia |
title_fullStr | Complement Activation Products in Patients with Chronic Schizophrenia |
title_full_unstemmed | Complement Activation Products in Patients with Chronic Schizophrenia |
title_short | Complement Activation Products in Patients with Chronic Schizophrenia |
title_sort | complement activation products in patients with chronic schizophrenia |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9967657/ https://www.ncbi.nlm.nih.gov/pubmed/36836111 http://dx.doi.org/10.3390/jcm12041577 |
work_keys_str_mv | AT rudkowskikrzysztof complementactivationproductsinpatientswithchronicschizophrenia AT waszczukkatarzyna complementactivationproductsinpatientswithchronicschizophrenia AT tyburskiernest complementactivationproductsinpatientswithchronicschizophrenia AT rekowodzinkatarzyna complementactivationproductsinpatientswithchronicschizophrenia AT plichtapiotr complementactivationproductsinpatientswithchronicschizophrenia AT podwalskipiotr complementactivationproductsinpatientswithchronicschizophrenia AT bieleckimaksymilian complementactivationproductsinpatientswithchronicschizophrenia AT makmonika complementactivationproductsinpatientswithchronicschizophrenia AT michalczykanna complementactivationproductsinpatientswithchronicschizophrenia AT tarnowskimaciej complementactivationproductsinpatientswithchronicschizophrenia AT sielatyckakatarzyna complementactivationproductsinpatientswithchronicschizophrenia AT budkowskamarta complementactivationproductsinpatientswithchronicschizophrenia AT łuczkowskakarolina complementactivationproductsinpatientswithchronicschizophrenia AT dołegowskabarbara complementactivationproductsinpatientswithchronicschizophrenia AT ratajczakmariuszz complementactivationproductsinpatientswithchronicschizophrenia AT samochowiecjerzy complementactivationproductsinpatientswithchronicschizophrenia AT kucharskamazurjolanta complementactivationproductsinpatientswithchronicschizophrenia AT saganleszek complementactivationproductsinpatientswithchronicschizophrenia |